Stockscreener 앱 받기
3.50
1.16%
0.04
시간 외 거래:
3.51
0.010
+0.29%
전일 마감가:
$3.46
열려 있는:
$3.49
하루 거래량:
10.47M
Relative Volume:
6.11
시가총액:
$233.22M
수익:
$80.00M
순이익/손실:
$-76.12M
주가수익비율:
-3.0528
EPS:
-1.1465
순현금흐름:
$-63.88M
1주 성능:
-0.28%
1개월 성능:
-47.68%
6개월 성능:
-71.03%
1년 성능:
-45.57%
1일 변동 폭
$3.45
$3.605
1주일 범위
$3.43
$3.64
52주 변동 폭
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.50 | 233.88M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire
Fulcrum plunges after discontinuing lead program - MSN
What's going on with Fulcrum Therapeutics stock on Thursday? - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. Files Form 8-K Report with SEC – Company Information and Key Details (June 2026) - Minichart
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Fulcrum Therapeutics Advances Restructuring with Leadership Changes - TipRanks
Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart - Stock Titan
Fulcrum Therapeutics, Inc. Announces Departure of Greg Tourangeau, Principal Accounting Officer - marketscreener.com
A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs - Yahoo Finance
Tang entities report 5,451,800‑share stake in Fulcrum (FULC) - Stock Titan
FULC stock crashes as cancer risk forces its only drug program's end - MSN
Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - NewMediaWire
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encour - The National Law Review
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire
Fulcrum Therapeutics, Inc. (FULC) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - NewMediaWire
Layoff Tracker: Fulcrum axes 85% of staff after walking away from lead asset - BioSpace
Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Investors to Inquire about Securities Investigation - ACCESS Newswire
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
What's Going On With Fulcrum Therapeutics Stock On Thursday? - Sahm
Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives - The Business Journals
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Reach Out - ACCESS Newswire
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring - Yahoo Finance
Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC) - GlobeNewswire
Fulcrum Therapeutics Undertakes Major Restructuring, Explores Strategic Alternatives - TipRanks
Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review - Stock Titan
Fulcrum Therapeutics, Inc. Engages Leerink Partners LLC as Financial Advisor to Assist in Reviewing Potential Strategic Alternatives - marketscreener.com
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud - Business Wire
Fulcrum Therapeutics to Cut Most of Staff After Ending Sickle-Cell-Drug Development - Moomoo
FULC Downgraded by JP Morgan -- Rating Changed to Underweight - GuruFocus
Fulcrum: 'Hold' On Pociredir Discontinuation And Strategic Alternatives Shift - Seeking Alpha
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - sharewise.com
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum T - GuruFocus
This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations - Moomoo
JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight - marketscreener.com
Goldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt By Investing.com - Investing.com Australia
FULC Downgraded by Stifel -- Price Target Lowered to $3.00 - GuruFocus
Goldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt - Investing.com UK
Goldman Sachs Suspends Rating on Fulcrum Therapeutics (FULC) - GuruFocus
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fulcrum Therapeutics Inc 주식 (FULC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gould Robert J | Director |
Jan 02 '26 |
Sale |
11.87 |
15,000 |
178,089 |
469,864 |
| Oltmans Curtis Gale | Chief Legal Officer |
Dec 15 '25 |
Sale |
12.92 |
3,452 |
44,600 |
10,252 |
2.60%
0.94%
자본화:
|
볼륨(24시간):